These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38458540)

  • 1. Broad antibody and T cell responses to Ebola, Sudan, and Bundibugyo ebolaviruses using mono- and multi-valent adjuvanted glycoprotein vaccines.
    Felgner J; Clarke E; Hernandez-Davies JE; Jan S; Wirchnianski AS; Jain A; Nakajima R; Jasinskas A; Strahsburger E; Chandran K; Bradfute S; Davies DH
    Antiviral Res; 2024 May; 225():105851. PubMed ID: 38458540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 4. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
    Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
    Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
    Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
    Gilchuk P; Guthals A; Bonissone SR; Shaw JB; Ilinykh PA; Huang K; Bombardi RG; Liang J; Grinyo A; Davidson E; Chen EC; Gunn BM; Alter G; Saphire EO; Doranz BJ; Bukreyev A; Zeitlin L; Castellana N; Crowe JE
    Front Immunol; 2021; 12():706757. PubMed ID: 34335620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.
    Bounds CE; Kwilas SA; Kuehne AI; Brannan JM; Bakken RR; Dye JM; Hooper JW; Dupuy LC; Ellefsen B; Hannaman D; Wu H; Jiao JA; Sullivan EJ; Schmaljohn CS
    PLoS One; 2015; 10(9):e0137786. PubMed ID: 26422247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.
    Gilchuk P; Kuzmina N; Ilinykh PA; Huang K; Gunn BM; Bryan A; Davidson E; Doranz BJ; Turner HL; Fusco ML; Bramble MS; Hoff NA; Binshtein E; Kose N; Flyak AI; Flinko R; Orlandi C; Carnahan R; Parrish EH; Sevy AM; Bombardi RG; Singh PK; Mukadi P; Muyembe-Tamfum JJ; Ohi MD; Saphire EO; Lewis GK; Alter G; Ward AB; Rimoin AW; Bukreyev A; Crowe JE
    Immunity; 2018 Aug; 49(2):363-374.e10. PubMed ID: 30029854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
    Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
    J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease.
    Brannan JM; Froude JW; Prugar LI; Bakken RR; Zak SE; Daye SP; Wilhelmsen CE; Dye JM
    J Infect Dis; 2015 Oct; 212 Suppl 2():S282-94. PubMed ID: 25943199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses.
    Wu F; Zhang S; Zhang Y; Mo R; Yan F; Wang H; Wong G; Chi H; Wang T; Feng N; Gao Y; Xia X; Zhao Y; Yang S
    Viruses; 2020 Jan; 12(1):. PubMed ID: 31947873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Single-Dose Intranasal Combination Panebolavirus Vaccine.
    Malherbe DC; Kimble JB; Atyeo C; Fischinger S; Meyer M; Cody SG; Hyde M; Alter G; Bukreyev A
    J Infect Dis; 2023 Nov; 228(Suppl 7):S648-S659. PubMed ID: 37469133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region.
    Schoeder CT; Gilchuk P; Sangha AK; Ledwitch KV; Malherbe DC; Zhang X; Binshtein E; Williamson LE; Martina CE; Dong J; Armstrong E; Sutton R; Nargi R; Rodriguez J; Kuzmina N; Fiala B; King NP; Bukreyev A; Crowe JE; Meiler J
    PLoS Pathog; 2022 May; 18(5):e1010518. PubMed ID: 35584193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced
    Chabot S; Gimie Y; Obeid K; Kim J; Meseda CA; Konduru K; Kaplan G; Sheng Fowler L; Weir JP; Peden K; Major ME
    J Virol; 2022 Sep; 96(18):e0116621. PubMed ID: 36069549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.
    Howell KA; Qiu X; Brannan JM; Bryan C; Davidson E; Holtsberg FW; Wec AZ; Shulenin S; Biggins JE; Douglas R; Enterlein SG; Turner HL; Pallesen J; Murin CD; He S; Kroeker A; Vu H; Herbert AS; Fusco ML; Nyakatura EK; Lai JR; Keck ZY; Foung SKH; Saphire EO; Zeitlin L; Ward AB; Chandran K; Doranz BJ; Kobinger GP; Dye JM; Aman MJ
    Cell Rep; 2016 May; 15(7):1514-1526. PubMed ID: 27160900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study.
    Diallo MSK; Ayouba A; Keita AK; Thaurignac G; Sow MS; Kpamou C; Barry TA; Msellati P; Etard JF; Peeters M; Ecochard R; Delaporte E; Toure A;
    Lancet Microbe; 2021 Dec; 2(12):e676-e684. PubMed ID: 35544108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses.
    Milligan JC; Davis CW; Yu X; Ilinykh PA; Huang K; Halfmann PJ; Cross RW; Borisevich V; Agans KN; Geisbert JB; Chennareddy C; Goff AJ; Piper AE; Hui S; Shaffer KCL; Buck T; Heinrich ML; Branco LM; Crozier I; Holbrook MR; Kuhn JH; Kawaoka Y; Glass PJ; Bukreyev A; Geisbert TW; Worwa G; Ahmed R; Saphire EO
    Cell; 2022 Mar; 185(6):995-1007.e18. PubMed ID: 35303429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.
    Wec AZ; Bornholdt ZA; He S; Herbert AS; Goodwin E; Wirchnianski AS; Gunn BM; Zhang Z; Zhu W; Liu G; Abelson DM; Moyer CL; Jangra RK; James RM; Bakken RR; Bohorova N; Bohorov O; Kim DH; Pauly MH; Velasco J; Bortz RH; Whaley KJ; Goldstein T; Anthony SJ; Alter G; Walker LM; Dye JM; Zeitlin L; Qiu X; Chandran K
    Cell Host Microbe; 2019 Jan; 25(1):39-48.e5. PubMed ID: 30629917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants.
    Hernandez-Davies JE; Dollinger EP; Pone EJ; Felgner J; Liang L; Strohmeier S; Jan S; Albin TJ; Jain A; Nakajima R; Jasinskas A; Krammer F; Esser-Kahn A; Felgner PL; Nie Q; Davies DH
    Sci Rep; 2022 Jun; 12(1):9198. PubMed ID: 35654904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.